J&J offers Rallybio $7M in info swap for trials of maternal-fetal disease

2024-04-10
·
交易
快速通道临床3期临床2期临床1期
There currently aren’t any approved therapies specifically targeting the prevention or prenatal treatment of fetal and neonatal alloimmune thrombocytopenia.
A few weeks ago, Johnson & Johnson nabbed FDA fast-track status for nipocalimab in fetal and neonatal alloimmfetal and neonatal alloimmune thrombocytopeniarma is making a combined cash and equity investment of over $7 million in Rallybio in order to get the biggest benefits from both companies' programs centered on this rare blood disorder.
Under the deal, rJohnson & Johnsonch RallyFDA will receive an upfronnipocalimabpaymfetal and neonatal alloimmune thrombocytopenia (FNAIT)IT therapy program as the biotech conducts a natural history study for RLYB212, a human monoRallybionti-HPA-1a antibody. RLYB212 is designed to prevent pregnant individuals from alloimmrare blood disorderstops a pregnant person's immune system from attacking fetal platelets and therefore reduces the risk of severe bleeding complications for the baby.
Rallybio will also be eligible to receive additional milestone payments of up to $3.7 millioJ&JFurthermore, J&J’s investment arm JJDC is putting down $6.6 million in equity for RallyBio.RLYB212anti-HPA-1a antibodyRLYB212bleeding
In return, Rallybio will share certain aggregated, anonymized natural history data from its FNAIT studies wiJ&JJ&J. The biotech wJJDCalso "disseminate information to its FNAIT sRallyBioes related to J&J’s research and development of its complementary therapeutic approaches aimed at reducing the risk of FNAIT," the company told Fierce.
Rallybio isRallybio the FNAIT natural history study with the mission of providing a modern dataset for HPA-1a alloimmunization frequency that is intended to support a future registrational study of RJ&J212. The biotech is slated to launch a phase 2 dose confirmation trial for RLYB212 among pregnant individuals with a higher risFiercelloimmunization and FNAIT in the second half of this year.
Rallybiois the only known clinical-stage therapy designed for pregnant individuals at risk of FNAIT who haven’t alloimmunized, according to RallyBio.RLYB212
RLYB212le, J&J is currently running a phase 3 trial of nipocalimab—a monoclonal antibody desigFNAITo target FcRn—among pregnant individuals RallyBioalready alloimmunized. While RLYB212 is designed to be preventative, nipocalimab is aimed at individuals who already have the alloantibodies that cause FNAIT.
There curreJ&Jy aren’t any approved therapies specificanipocalimabng the prevention or prenatal treatment ofFcRnIT, Rallybio noted in an April 10 release.RLYB212nipocalimab
“Our complementary approaches, if successful, would ensure that pregnant individuals at risk of developing FNAIT have a potential treatment option—regardless of their alloimmunization status,” Rallybio CEO Stephen Uden, M.D., said in the release. “Together, we can more effectively and expeditiously drive awareness of FNAIT, emphasize the importance of screening pregnant individuals for their risk of developing FNAIT and advance our complementary therapeutic approaches.”
The Big Pharma partnership comes a little more than two months after Rallybio sent 45% of its staff packing and zoomed in on two phase 2-ready programs—one of which is RLYB212—to extend its cash runway into the middle of 2026. The other program, RLYB116, is a C5 inhibitor that the biotech believes could potentially treat several diseases involving complement dysregulation.
Rallybio entered 2024 with cash, cash equivalents and marketable securities of $109.9 million.RLYB116C5 inhibitorC5
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
-
靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路,让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。